Author
Listed:
- Xuetong Wang
(University of Science and Technology of China
Chinese Academy of Science
Southeast University)
- Tongfeng Liu
(Southeast University
Medical School of Guizhou University)
- Yifei Li
(Southeast University
Nanjing University of Chinese Medicine)
- Ao Ding
(Southeast University
Nanjing University of Chinese Medicine)
- Chang Zhang
(Southeast University
Guangzhou Medical University)
- Yinmin Gu
(Southeast University)
- Xujie Zhao
(Southeast University)
- Shuwen Cheng
(Southeast University
Medical School of Nanjing University)
- Tianyou Cheng
(Shanxi Academy of Advanced Research and Innovation)
- Songzhe Wu
(Southeast University)
- Liqiang Duan
(Shanxi Academy of Advanced Research and Innovation)
- Jihang Zhang
(Southeast University
Medical School of Guizhou University)
- Rong Yin
(Nanjing Medical University Affiliated Cancer Hospital)
- Man Shang
(Women’ s Hospital of Nanjing Medical University (Nanjing Women and Children’ s Healthcare Hospital))
- Shan Gao
(University of Science and Technology of China
Chinese Academy of Science
Southeast University)
Abstract
The immune checkpoint receptor, programmed cell death 1 (PD-1, encoded by PDCD1), mediates the immune escape of cancer, but whether PD-1 splicing isoforms contribute to this process is still unclear. Here, we identify an alternative splicing isoform of human PD-1, which carries a 28-base pairs extension retained from 5′ region of intron 2 (PD-1^28), is expressed in peripheral T cells and tumor infiltrating lymphocytes. PD-1^28 expression is induced on T cells upon activation and is regulated by an RNA binding protein, TAF15. Functionally, PD-1^28 inhibits T cell proliferation, cytokine production, and tumor cell killing in vitro. In vivo, T cell-specific exogenous expression of PD-1^28 promotes tumor growth in both a syngeneic mouse tumor model and humanized NOG mice inoculated with human lung cancer cells. Our study thus demonstrates that PD-1^28 functions as an immune checkpoint, and may contribute to resistance to immune checkpoint blockade therapy.
Suggested Citation
Xuetong Wang & Tongfeng Liu & Yifei Li & Ao Ding & Chang Zhang & Yinmin Gu & Xujie Zhao & Shuwen Cheng & Tianyou Cheng & Songzhe Wu & Liqiang Duan & Jihang Zhang & Rong Yin & Man Shang & Shan Gao, 2024.
"A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint,"
Nature Communications, Nature, vol. 15(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53561-2
DOI: 10.1038/s41467-024-53561-2
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53561-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.